Chemours (NYSE:CC) Shares Gap Up – What’s Next?

The Chemours Company (NYSE:CC) shares gapped up before the market opened on Tuesday. The stock had previously closed at $13.16, but opened at $14.48. Chemours shares last traded at $13.3550, with a volume of 260,401 shares.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours issued fourth-quarter 2026 revenue guidance of $1.7 billion to $1.8 billion, well above the $1.4 billion analyst consensus. Full-year revenue guidance of $5.9 billion was in line with expectations, providing some support for the outlook.
• Positive Sentiment: The company launched its Faizeon two-phase liquid-cooling portfolio for AI, high-performance computing, and high-density data centers. The products are designed to manage rising computing heat loads while reducing energy and water consumption, potentially expanding Chemours’ exposure to data-center growth. Chemours Launches Faizeon Two-Phase Liquid Cooling Solutions for AI Data Centers
• Positive Sentiment: At least one recent analyst article upgraded Chemours, arguing that patient investors could benefit from a potential recovery. Chemours: Patient Investors Can Be Rewarded
• Neutral Sentiment: Third-quarter revenue rose 3% year over year to $1.54 billion, slightly above the $1.53 billion consensus estimate. However, management reported adjusted EPS of $0.21 versus the $0.26 expected.
• Negative Sentiment: The earnings shortfall, declining EPS from $0.40 a year earlier, and a reported negative net margin of 5% raise concerns about profitability and operating momentum. Chemours Reports Third Quarter Results
• Negative Sentiment: Several law firms publicized a securities class action alleging that Chemours misrepresented demand for its Opteon products before a major stock decline and subsequent guidance concerns. The allegations are not proven, but the litigation creates legal, reputational, and potential financial risks for investors; the lead-plaintiff deadline is December 7, 2026. Chemours Securities Fraud Class Action Notice

Analyst Ratings Changes

A number of brokerages recently weighed in on CC. Weiss Ratings cut shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. Morgan Stanley set a $18.00 price objective on shares of Chemours in a research note on Monday, August 10th. UBS Group reduced their target price on shares of Chemours from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Monday, October 5th. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a report on Thursday, September 10th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $16.00 target price on shares of Chemours in a research note on Friday, October 9th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Chemours presently has an average rating of “Hold” and a consensus price target of $17.73.

Chemours Trading Up 2.3%

The stock has a market capitalization of $2.03 billion, a PE ratio of -7.03 and a beta of 1.41. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The business’s 50-day moving average is $14.17 and its two-hundred day moving average is $18.26.

Chemours (NYSE:CC) last released its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 EPS for the quarter, missing the consensus estimate of $0.26 by ($0.05). The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.53 billion. Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted $0.40 EPS. As a group, equities research analysts anticipate that The Chemours Company will post 0.83 earnings per share for the current year.

Chemours Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Monday, November 16th. Chemours’s dividend payout ratio is currently -18.32%.

Insider Activity at Chemours

In other Chemours news, CEO Denise Dignam acquired 3,378 shares of the stock in a transaction on Tuesday, August 11th. The shares were bought at an average price of $14.95 per share, with a total value of $50,501.10. Following the acquisition, the chief executive officer owned 339,916 shares of the company’s stock, valued at $5,081,744.20. This trade represents a 1.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of the stock in a transaction on Wednesday, August 12th. The stock was acquired at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the acquisition, the insider directly owned 58,547 shares in the company, valued at $909,234.91. This represents a 3.42% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 8,663 shares of company stock worth $130,601 over the last 90 days. Company insiders own 0.85% of the company’s stock.

Institutional Trading of Chemours

A number of institutional investors have recently modified their holdings of CC. Deutsche Bank AG purchased a new stake in shares of Chemours during the 2nd quarter worth approximately $3,291,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Chemours in the 2nd quarter worth approximately $1,522,000. BlackRock Inc. acquired a new stake in shares of Chemours in the 2nd quarter worth approximately $477,769,000. Jefferies Financial Group Inc. purchased a new position in Chemours in the 2nd quarter valued at approximately $15,996,000. Finally, Old West Investment Management LLC purchased a new position in Chemours in the 2nd quarter valued at approximately $7,152,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.